Associated equity: Context Therapeutics
Context Therapeutics is a clinical-stage biopharma company developing therapeutics for solid tumors. The core pipeline focus is now on CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, which is in preclinical development with plans for an IND application filing in Q124.
Context Therapeutics — 4 videos in collection
Context Therapeutics (Nasdaq: CNTX) is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers. The company’s robust clinical programme for lead candidate onapristone extended release (ONA-XR) comprises three Phase II clinical trials and one Phase Ib/II clinical trial in hormone-driven breast, ovarian and endometrial cancer. ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. In this webinar, Context’s team and presenters from the American Association for Cancer Research (AACR) conference discuss the important company results presented at the AACR Annual Meeting 2022.
Get access to the very latest content matched to your personal investment style.